Third dose mRNA vaccine offers stronger protection against COVID-19 hospitalization in immunocompromised: study

Published January 28, 2022, 7:28 AM

by Xinhua

A third COVID-19 mRNA vaccine dose provides improved protection against COVID-19-associated hospitalization among immunocompromised adults, according to a new study published by the U.S. Centers for Disease Control and Prevention (CDC) Thursday.

In the study involving 2,952 hospitalized adults, researchers found that a third dose increased vaccine effectiveness against hospitalization from 69 percent to 88 percent among the immunocompromised, and 82 percent to 97 percent among those without immune-compromising conditions.

The third dose was defined as a full dose in immunocompromised people or a booster dose among immunocompetent adults.

These findings underscore the importance of immunocompromised adults obtaining a third mRNA vaccine dose 28 days after the second vaccine dose, and of immunocompetent adults receiving a third dose five months after the second dose, according to the CDC.

 
CLICK HERE TO SIGN-UP
 

YOU MAY ALSO LIKE

["news","world","news"]
[2918906,3004110,3004107,3004059,3004043,3004036,3004013]